Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
Skin InfectionBacterial InfectionThe purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.
Cantharidin and Occlusion in Verruca Epithelium
Common WartWarts Hand12 moreThis is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
Staphylococcal Skin InfectionThe purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections...
Skin DiseasesInfectious3 moreThe purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Condylomata AcuminataPapillomavirus Infections9 moreThis is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW). This study is divided into two parts (Part A and Part B). Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups prior to progressing to enrollment in Part B. Part A & B will enroll a approximately 108 subjects completing 4 treatment applications every 21 days and continuing with follow-up assessments at Day 84, 112 and 147.
Effect of an Antiseptic Solution on the Skin Microbiome
Skin DiseasesInfectiousThe objective of this study is simulate the clinical use of an antiseptic solution in a 24 hour window and the recovery to baseline conditions at 1 month following application. Efficacy will be simulated as the capacity of the material to reduce or clear the skin bacterial population from a representative skin area: the anteromedial forearm.
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus...
Skin DiseasesInfectiousThe aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
Staphylococcal Skin InfectionsThis was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.
A Study for Patients With Complicated Skin and Skin Structure Infections
Staphylococcal Skin InfectionsWounds and Injuries3 moreTwo Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed. The pharmacokinetic profile of oritavancin in humans suggests that oritavancin has the potential to be used safely and effectively when given either as a single dose or as an infrequent dose for cSSSI. Data from animals support this theory. SIMPLIFI has been designed to evaluate the efficacy and safety of either a single dose of oritavancin or an infrequent dose of oritavancin (First dose on Day one with an option for a second dose on Day five) compared to the previously studied dosing regimen of 200mg oritavancin given once daily for 3 to 7 days.
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus...
Skin InfectionPrimary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA. Secondary Objective(s): To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due to MRSA To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549. To assess the safety of multiple doses of CG400459